Aciphex

Patients must complete this form before they can participate in the Patience Assistance Program. I allow my doctor s ; , any other health care providers, and my health plan or insurers to give medical information relating to my use or need for ACIPHEX rabeprazole sodium ; to Lash Group. Lash Group runs the ACIPHEX Patient Assistance Program the "Program" ; for Johnson & Johnson Health Care Systems Inc. Johnson & Johnson Health Care Systems Inc. manages the ACIPHEX Patient Assistance Program on behalf of its affiliate PriCara, Unit of Ortho-McNeil, Inc., and Eisai Inc. the manufacturer of ACIPHEX. ACIPHEX is manufactured and marketed by Eisai Inc. and marketed by PriCara, Unit of Ortho-McNeil, Inc. This information can include spoken or written facts about my health and payment benefits. It can include copies of records from my health care providers or health plans about my health or health care. Lash Group and Johnson & Johnson Health Care Systems Inc. will use and give out this information to see if I qualify for the Program and to run the Program. People who work for and with Lash Group, Johnson & Johnson Health Care Systems Inc. and Eisai Inc. may also see my information, but they may use it only to help me get assistance with the costs of my drugs and to operate the Program. I understand that they will make every effort to keep my information private, but if it is accidentally given out, federal privacy laws will not protect it. This Authorization will last until I no longer participating in the Program. If I change my mind before that time, I can tell my health care providers and my insurers in writing that I do not want them to share any more information with Lash Group or Johnson & Johnson Health Care Systems Inc., and Eisai Inc. but it will not change any actions they took before I told them. I know that I have a right to see or copy the information my health care providers or insurers have given to Lash Group, Johnson & Johnson Health Care Systems Inc., and Eisai Inc. I KNOW THAT I MAY REFUSE TO SIGN THIS FORM. My choice about whether to sign this form will not change the way my health care providers or insurers treat me. If I refuse to sign this form, I know that this means I may no longer be able to receive assistance from the Program and bentyl. Many others, so that people with psychiatric disabilities are guaranteed their fundamental rights as American citizens. NCD has also concluded that one of the reasons public policy concerning psychiatric disability is so different from that concerning other disabilities is the systematic exclusion of people with psychiatric disabilities from policymaking. It is rare that people with psychiatric disabilities are heard in public-policy forums, and when they are, it is usually in token numbers. NCD's hearing was unique because it focused its attention on the direct experiences of people with psychiatric disabilities themselves, and their calls for fundamental change. The foremost change that is needed, as referred to by speaker after speaker, is the elimination of coercion from the provision of mental health services. Involuntary commitment and forced treatment, which often go unquestioned in discussions of mental health policy, were described again and again as being among the most painful and difficult experiences of people's lives. In addition, coercion was repeatedly noted as being a barrier to seeking out voluntary treatment, since people knew that once they entered the treatment system they could be coerced or involuntarily committed at any point. At a time when American citizens are being urged to do away with the stigma of mental illness and to voluntarily seek treatment for emotional difficulties, it becomes particularly important to ensure that people are able to do so without surrendering their fundamental rights. Therefore, NCD recommends that the use of involuntary treatments, such as forced drugging and inpatient and outpatient commitment laws, should be viewed as inherently suspect and as incompatible with the principles of self-determination. Public policy should be directed toward establishing a totally voluntary mental health system. NCD also recommends that aversive treatments, which involve the infliction of pain or the restriction of movement for purposes of changing behavior, should be banned, since they are also incompatible with self-determination principles. Practices that would often be illegal if administered to people without disabilities are routinely used on people with psychiatric disabilities in the name of "treatment." Such practices should shock the consciences of all Americans. 4. Two large trials of statins to treat alzheimers are underway and zantac.

Source MMW Fortschritte der Medizin 15 Feb 2007, vol. 149, no. 7, p. 36-8, 40, ISSN: 1438-3276. Author s ; Roesner-D, Virchow-J-C. Abstract Anamnestic factors of importance are, in particular, acute attacks of shortness of breath, dry cough and symptoms of concomitant rhinoconjunctivitis. Wheezing and other rhonchi are the typical findings on auscultation. Of decisive importance for the diagnosis is spirometry showing reduced values for the one-second forced vital capacity and the Tiffeneau index. After administration of a beta sympathomimetic, an obstruction can be at least partially reversed. An absent primary obstruction should be inducible by unspecific provocation. On the basis of symptoms and lung function, bronchial asthma is divided into four stages. For establishing the allergic genesis of the illness, additional anamnestic data, in particular concerning the nature of possible allergens, are needed before sensitization is proven by the prick test and the detection of specific IgE antibodies. An equivocal situation can be clarified with the aid of specific nasal--more rarely also bronchial--provocation. Publication date 20070215.
Variables related to an early age at menopause influence the risk for pancreatic cancer, and variables associated with a later age at menopause reduce the risk, according to the Iowa Women's Health Study, a prospective, population-based study designed to examine risk factors for breast and other cancers. The cohort of 37, 459 peri- and postmenopausal women aged 55-69 at baseline ; provided information at baseline in 1986 and were followed until 2003. The baseline questionnaire asked about body size, lifestyle and sociodemographic factors, diet, and medical and reproductive history. This portion of the study evaluated the association between the incidence of pancreatic cancer and reproductive characteristics. The hypothesis for an association was based upon the facts that pancreatic cancer is more common in men than in women, steroid hormone receptors occur in the pancreas, and antiestrogenic agents inhibit the growth of pancreatic cancer in human models and carafate.
Aciphex r ; is classified as a proton pump inhibitor that effectively suppresses gastric acid secretion while inhibiting enzyme activity during the last phase of stomach acid secretion. Practical journal of integrated chinese and western medicines , 1997; 5 shi yong zhong xi yi jie he za zhi and metoclopramide. [P-9125] THE USE OF PREGABALIN LYRICA ; TO TREAT VAGAL NEURALGIA: A CASE REPORT Irina Lokshina, Carole W. Agin, Robert Katz. Department of Anesthesiology, State University of New York at Stony Brook, Stony Brook, New York In December, 2004, a 53 year old white male began to suffer from a burning sore throat localized to the right side of the pharynx. After ruling out an active infection, laryngoscopy was performed and laryngopharyngeal reflux LPR ; was diagnosed. Treatment with Nexium over the course of three months produced no improvement. Nexium was switched to Acophex along with Famodipine, resulting in improvement in symptoms, but having no effect on the pain. In December 2005, repeat laryngoscopy revealed findings consistent with vagal neuralgia and Pregabalin was prescribed. Over the next week, the patient's pain began to resolve and continued to improve for approximately one month. The patient described his pain as approximately one to two on a ten point scale, whereas prior to starting pregabalin, he had described it as eight out of ten. Thus, we describe a case of a patient suffering from LPR plus vagal neuralgia, whose symptoms were significantly relieved by the use of Pregabalin. Introduction Pregabalin Lyrica ; is a recently introduced anti-seizure medication used to treat pain of neurogenic origin.1 We describe a case of a patient suffering from laryngopharyngeal reflux LPR ; and vagal neuralgia, whose symptoms were significantly relieved by the use of Pregabalin. The patient's symptoms were relieved to the point that scheduled surgical correction was unnecessary. Case Report In December, 2004, a 53 year old white male began to suffer from a burning sore throat localized to the right side of the pharynx. Keflex 500 mg PO for two weeks resulted in no change in symptoms. In January, 2005, an indirect laryngoscopy was performed and LPR was diagnosed. Treatment with Nexium 20 mg once daily for two months resulted in no improvement, with the patient's symptoms gradually worsening. Nexium was increased to twice daily with no effect. In April, 2005, Nexium was switched to Ackphex 20 mg PO twice a day. Upper endoscopy at this time was normal. In July, 2005, a 24 hour double pH probe revealed 66 episodes of acid reflux in the lower esophagus and 16 in the upper esophagus. Famodipine 10 mg PO twice a day was added, with the symptoms of cough and globus sensation significantly improving, but the pain remaining. In December, 2005, repeat pH testing revealed a positive response to medication. In January, 2006, repeat laryngoscopy and sensory testing of the larynx revealed findings consistent with the diagnosis of LPR and vagal neuralgia, with specific involvement of the right superior laryngeal nerve. Pregabalin, 100 mg PO, twice a day was prescribed. Over the next week, the patient's right sided sore throat began to resolve and continued to improve for approximately one month, after which there was no further improvement. The patient described his pain as approximately one to two on a ten point scale, whereas prior to starting pregabalin, he had described it as eight out of ten. Discussion The severe burning nature of the throat pain, along with its localization to the right side and its failure to resolve with medication, cast doubt upon the pain being caused by LPR.2 We suspected neuropathic pain, which was supported by the bowing and decreased abduction of the vocal cord upon laryngoscopy. Futhermore, the patient reported a recent respiratory infection. 3 These findings led to a diagnosis of vagal neuralgia. Pregabalin is a recently introduced anti-seizure medication. It has not previously been reported to be effective in vagal neuralgia, a relatively rare condition, often causing burning pain, sometimes so severe as to cause clinical depression and suicidal ideations. While the exact mechanism of action of Pregabalin is unknown, it has been shown to be effective in treating neuropathic pain. Interestingly, in tandem with its analgesic properties, Pregabalin has been shown to be quite effective as an antidepressant. Thus, we believe that Pregabalin is an effective treatment to the somatic and psychic symptoms caused by vagal neuralgia. References 1 ; Shneker BF, et.al. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother. 2005 Dec; 39 12 ; : 2029-37. 2 ; Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005; 294: 1534-40. ; Amin MR, et.al. Vagal neuropathy after upper respiratory infection: a viral etiology? J Otolaryng Jul 2001; 22 4 ; : 251-6. Date: Sunday, December 10, 2006 Session Info: Poster Presentation II: 11: 00AM - 1: 00PM 1100-1300 ; Presentation Time: 11: 00 AM. New York State offers numerous programs and services designed to enhance the lives of seniors and their families. The New York State Office for the Aging has prepared a comprehensive guide to help navigate and access available resources. The following is a partial listing. For more information, call the toll-free Senior Citizen's Hot Line at 1-800-342-9871 weekdays between 8 a.m. and 4 p.m. ; or visit : aging ate.ny and click on the icon for resource guide. Long Term Elder Abuse Care Prevention Ombudsman Sadly, many seniors become victims of Program HEAP Home Energy Office of Refugee EPIC Elderly Assistance Program ; and Immigration Pharmaceutical This program provides Services ORIS ; Insurance ORIS provides a Citicash to help pay heating Coverage and allopurinol. Gastrointestinal pain, chest pain, headache ; and injuries e.g., fractures, sprains, lacerations ; .103 Chronic pain is also a problem of epidemic proportions. About 50 million of the estimated 75 million Americans who live with "serious pain" suffer from chronic pain.104 Many have been living with their pain for more than 5 years and experience pain almost 6 days a week.14 A survey of self-help organization members suggested that back and neck pain, myofascial pain fibromyalgia, headache, arthritis pain, and neuropathic pain are the most common types of CNCP.105 Low back pain, arthritis, and migraine headache alone account for pain in tens of millions of Americans.88!

Thousands of cases of bacterial illness occur every year, many of them fatal.
Type Policy Drug Therapy Codes N A Evidence Basis for Policy Standard of care. The procedure, device, or drug is accepted medical practice as evidenced by an abundance of scientific literature and well-designed clinical trials. Description Proton Pump Inhibitors requiring prior authorization and subject to quantity limits: Sciphex rabeprazole ; Prilosec omeprazole ; brand only Protonix pantoprazole ; Zegerid omeprazole sodium bicarbonate ; Prior authorization is not required for the following Proton Pump Inhibitors but are subject to quantity limits: Nexium esomeprazole ; Prevacid lansoprazole ; products No prior authorization is required for the treatment of H. pylori with duodenal ulcer disease for up to 2 doses per day up to 14 days of therapy for those products not requiring prior authorization. Proton Pump Inhibitors PPIs ; suppress gastric acid secretion by specific inhibition of the adenosine triphosphate enzyme system at the secretory surface of the gastric parietal cell. Therefore, they block the final step of acid production. All PPIs are considered to be therapeutically equivalent and interchangeable in the management of gastric or duodenal ulcers, gastroesophageal reflux disease GERD ; , erosive esophagitis EE ; , and eradication of H. pylori infections. The literature does not demonstrate significant superiority of one or more PPI in comparison to the others in safety and or efficacy. Indications Criteria The use of Aciphex, Zegerid, Protonix, or Prilosec brand ; may be medically necessary if: The member has experienced treatment failure or significant intolerance e.g. sensitivity, drug allergy, adverse effect ; to ALL formulary PPIs at the appropriate dose and proventil. Astaxanthin supplement by ray sahelian, astaxanthin health benefit what you will find on this page astaxanthin information astaxanthin for sale eyesight rx with astaxanthin - formulated by ray sahelian, for vision enhancement astaxanthin is a carotenoid made by plants and algae, and found in marine seafood such as salmon. Exhibit 99.15 Johnson & Johnson 2003 First Quarter EPS Rose 16.9% on Sales Increase of 12.3% New Brunswick, NJ April 15, 2003 ; -- Johnson & Johnson today announced sales for the first quarter of .8 billion, an increase of 12.3% over the prior year. Excluding the impact of currency, worldwide sales increased 8.1%. Domestic sales were up 8.9%, while international sales increased 6.9% on an operational basis. Net earnings and diluted earnings per share for the quarter were .1 billion and $.69, increases of 12.9% and 16.9%, respectively, as compared to the same period in 2002. These amounts include after-tax special charges of million taken in the first quarter of 2003 for in-process research and development costs associated with the acquisitions of 3-Dimensional Pharmaceuticals, Inc. and Orquest, Inc. "I pleased with our ability to continue to deliver solid results in sales and earnings despite the challenges of intense competition, " said William C. Weldon, Chairman and Chief Executive Officer. "The breadth of our businesses in human health care serves us well, an excellent example this quarter being the strong performance of our worldwide consumer businesses." Mr. Weldon also stated, "The key to our long-term consistent performance is our ongoing investment in science and technology." Worldwide Pharmaceutical sales of .7 billion for the first quarter of 2003 represented an increase of 11.6% versus the prior year on a reported basis and 7.8% operationally. Domestic sales increased 10.3%, while international sales increased 14.7%. Sales growth reflects the strong performance of REMICADE, a treatment for rheumatoid arthritis and Crohn's disease; DURAGESIC, a transdermal patch for chronic pain; TOPAMAX, an antiepileptic; ACIPHEX PARIET, a proton pump inhibitor for gastrointestinal disorders, and RISPERDAL, an antipsychotic medication. PROCRIT EPREX, a product for the treatment of anemia, was impacted by increased competition and had minimal reported growth. During the first quarter, the Company announced a definitive agreement to acquire Scios, Inc., a biopharmaceutical company with a marketed product for cardiovascular disease and research projects focused on auto-immune diseases. Scios' product NATRECOR is a novel agent approved for congestive heart failure and has several significant advantages over existing therapies. Their research and development program includes several potential new treatments for pain and inflammatory diseases, including an advanced p-38 kinase inhibitor program. The transaction is valued at approximately .4 billion, net of cash, and is expected to close later this month. Also in the quarter, the Company announced and completed the acquisition of 3-Dimensional Pharmaceuticals, Inc., a company with a technology platform focused on the discovery and development of potential new drugs in early stage development for the treatment of cardiovascular disorders, oncology and inflammation. The transaction is valued at million, net of cash. The Company also received U.S. Food and Drug Administration FDA ; approval for REMICADE infliximab ; for the additional indication of long-term treatment of fistulizing Crohn's disease, a chronic inflammatory bowel disorder that commonly affects the lower part of the small and large intestine, as well as FLEXERIL cyclobenzaprine HCl ; 5 mg tablets for the treatment of muscle spasm associated with painful musculoskeletal conditions. In April, the Company received FDA approval for RISPERDAL M-TAB risperidone ; , a fast dissolving form of the schizophrenia medication that dissolves in seconds when placed in the mouth. Worldwide Medical Devices and Diagnostics achieved sales of .4 billion in the first quarter of 2003, which represented an increase over the prior year of 13.7% on a reported basis and 8.0% operationally. Domestic and international sales increased 5.1% and 24.8%, respectively. DePuy's orthopaedic joint reconstruction and spinal products, and Ethicon Endo-Surgery's minimally invasive surgical products achieved very strong sales growth. Also contributing to the overall performance of the segment were solid results from Cordis' circulatory disease management products and Ethicon's wound care and women's health products. During the quarter, the Company completed the acquisition of Orquest, Inc., a privately held biotechnology company focused on developing biologically-based implants for orthopaedics and spine surgery. Orquest's principal product, HEALOS Bone Graft Material, is designed to reduce the time and pain associated with standard bone graft harvesting and represents a therapeutic advance for patients requiring bone graft material for spine fusion or other surgery. Worldwide Consumer sales were .8 billion in the first quarter of 2003, an increase of 11.7% over the prior year on a reported basis and 9.6% operationally. Domestic sales increased 11.1%, while international sales increased 12.4%. Consumer sales experienced strong growth in NEUTROGENA, CLEAN & CLEAR and AVEENO skin care products and SPLENDA sweetener products, as well as broad-based growth in the Consumer Pharmaceuticals and Wound Care franchises. Johnson & Johnson, with approximately 110, 300 employees, is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. Johnson & Johnson has more than 200 operating companies in 54 countries around the world, selling products in more than 175 countries.

Registration number: Name of medicine: Dosage form: Active ingredients: Conditions of registration: Applicant: Manufacturer: JANSSEN PHARMACEUTICA PTY ; LTD EISAI CO LTD, KODAMA-GUN, SAITAMA-KEN, JAPAN UNIPACK LTD, SHOTGATE, ESSEX, UK CILAG AG, SCHAFFHAUSEN, SWITZERLAND JANSSEN PHARMACEUTICA, HALFWAY HOUSE, RSA EISAI CO LTD, KODAMA-GUN, SAITAMA-KEN, JAPAN CILAG AG, SCHAFFHAUSEN, SWITZERLAND THE BOOTS CO PLC. NOTTINGHAM UK JANSSEN PHARMACEUTICA, HALFWAY HOUSE, RSA ACIPHEX 20 TABLET EACH TABLET CONTAINS: RABEPRAZOLE SODIUM. If the pain is a dull ache, it is most likely that you simply have put strain on a muscle and stretching it will increase the range of motion and eventually allow it to heal and the back pain should dissipate.

I think that the swelling you describe is more likely to be due to a perineal hernia than to megacolon, though, just based on what we see in our practice and buy protonix.

In view of the known complications of GH excess and their adverse influence on cardiovascular morbidity and mortality, treatment of all patients with acromegaly is indicated. The consensus opinion of practically all authorities in the field is that transsphenoidal adenomectomy is the treatment of choice for GH-secreting adenomas. The goals of treatment should be those set earlier for all patients with pituitary tumor, including: normalizing GH-secretion, preserving normal pituitary function and reversing the mechanical effects of the tumor on surrounding structures. These goals can be achieved in approximately 50% of patients with acromegaly after adenomectomy. The main predictors of outcome after surgery include tumor size and location, preoperative GH concentrations, and the expertise of the surgeon Lissett et al. 1998, Melmed et al. 1998, Swearingen et al. 1998 ; . After complete surgical removal of the tumor, plasma IGF-I and both basal GH concentrations and its responses to dynamic stimulation become normal. Recurrences in these patients are rare with prolonged follow-up Arafah et al. 1987 ; . The most sensitive predictor of outcome after surgery remains a GH concentration within the first week after operation, that is less than 2 g l Valdemarsson et al. 2000 ; . However, normal basal postoperative serum GH and IGF-I are not sufficient criteria for complete resection of the adenoma, as the responses to stimulation and suppression tests have also to be normal. Even though some patients might have normal basal serum GH and IGF-I concentrations post-operatively, those who have persistent abnormalities to.
The esophagus is the tube that carries food from the mouth to the stomach. When stomach acid touches the lining of the esophagus, it can cause a burning feeling in the chest or throat, commonly called heartburn. Gastroesophageal reflux disease GERD ; occurs when the ring of muscle at the bottom of the esophagus just before the stomach does not close properly and allows stomach juices to repeatedly reflux back up ; into the esophagus. If you have heartburn symptoms every now and then, it is probably not serious. If you have them several times a week, however, it may be a sign of GERD. This condition can lead to esophagitis an inflamed lining of the esophagus ; , narrowing of the esophagus, bleeding, or trouble swallowing. Lifestyle changes and over-the-counter medicines no prescription required ; provide relief for most people with GERD. Doctors advise a simple approach at first eat smaller portions of food, do not eat close to bedtime, raise the head of your bed, maintain a healthy weight, avoid foods and drinks that can irritate your stomach such as caffeine and alcohol ; , and stop smoking. Over-the-counter medicines such as Tums, Pepto-Bismol, and Pepcid may also help. If these simple things do not work, or if you have alarm symptoms see below ; , it is important to discuss the problem with your doctor. This is especially important for people over 65, who are at risk for more severe complications from GERD. Alarm symptoms: Difficulty or sharp pain with swallowing Unexplained weight loss or loss of appetite Bloody stool Vomiting History of iron deficiency anemia Heartburn symptoms starting after age 50 Doctors can look into the esophagus with an endoscope and see whether there is inflammation or blockage. Proton pump inhibitors Prilosec, Nexium, Prevacid, Protonix, AcipHex ; are recommended as a first line of treatment for elderly patients with GERD and esophagitis. Studies show that they are more effective than H2 blockers Tagamet, Pepcid AC, Zantac ; for treating more serious disorders related to heartburn. Only a few people need surgery to repair this disorder. There are several options, including laparoscopic surgery done with the aid of a tiny camera placed inside the body. The important thing to remember is that you do not have to suffer from heartburn and GERD. Talk to your doctor about your symptoms and what will work best for you.

DIGESTIVE AIDS ASSORTED GI GI - ANTIPERISTALTIC AGENTS * Preferred drugs that used to require diag codes still require diag codes unless indicated otherwise. * Use PA Form # 20420 DIPHENOXYLATE ANTI-DIARRHEAL TABS DIPHENOXYLATE ATROPINE IMODIUM A-D TABS LOPERAMIDE HCL CAPS LOPERAMIDE HCL LIQD OPIUM TINCTURE TINC PAREGORIC TINC GI - ANTIDIARRHEAL ANTACID MISC. ALU-CAP CAPS ANTACID CHEW ATROPINE SULFATE SOLN BENTYL SYRP BISMATROL CALCIUM ANTACID CALCIUM CARBONATE CAL-GEST ANTACID CHEW CHEWABLE ANTACID CHEW DICYCLOMINE HCL GAVISCON SUSP HAPONAL TABS HYOSCYAMINE SULFATE IMODIUM ADVANCED CHEW KAOPECTATE K-PEC LIQD K-PEK SUSP MAALOX MAGNESIUM OXIDE TABS MAG-OX 400 TABS MAG-OXIDE TABS PAMINE TABS PINK BISMUTH PROPANTHELINE BROMIDE TABS ROBINUL SAL-TROPINE TABS SCOPOLAMINE HYDROBROMIDE SODIUM BICARBONATE TABS TUMS V-R STOMACH RELIEF SUSP X-STR CHEW ANTACID CHEW GI - H2-ANTAGONISTS CIMETIDINE FAMOTIDINE RANITIDINE V-R ACID REDUCER TABS AXID CAPS AXID AR TABS NIZATIDINE CAPS PEPCID PEPCID AC TAGAMET TABS ZANTAC1 GI - PROTON PUMP INHIBITOR PREVACID CPDR OTC PRILOSEC PROTONIX TBEC NEXIUM CPDR GI - ULCER ANTI-INFECTIVE HELIDAC 5 6 8 ACIPHEX TBEC OMEPRAZOLE CPDR PREVACID ORAL SUSP PREVACID SOLUTABS * PRILOSEC CPDR Use PA Form # 20420 1. Zantac syrup available without PA to users less than 6 years old. Use PA Form # 10220 ANTACID EXTRA STRENGTH CHEW B & O 15-A SUPPRETTE SUPP B & O 16-A SUPPRETTE SUPP BELLADONNA ALKALOIDS & OP BENTYL TABS CHILDRENS MYLANTA CHEW LEVBID TB12 LEVSIN ELIX LEVSIN TABS LEVSIN SL SUBL NULEV TBDP URO-MAG CAPS Use PA Form # 20420 or 10220 if applicable ; LOFENE TABS LONOX TABS MOTOFEN TABS SB ANTI-DIARRHEA TABS. Thu, 26 oct 2006 : 23 gmt ; aciphex side effects : i tired of the medications i'm taking for gerd not working.

Order generic Aciphex